Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557045 · ClinicalTrials.gov registry record · Phase 1
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 332
- Enrollment target
- 14
- Study locations
NCT05557045: Recruiting Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by Jazz Pharmaceuticals.
NCT05557045 is a Phase 1 study of Solid Tumor and Advanced Cancer that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 332 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (51% higher). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05557045, a Phase 1 study of Solid Tumor and Advanced Cancer, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 332 participants
- Enrollment target
- 14
- Study locations
Study Summary
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Conditions Studied
Interventions
- DRUG JZP815
Study Locations (14)
Texas
- Texas Oncology- Central South - Austin
- University of Texas MD Anderson Cancer Center - Houston
- Texas Oncology- Gulf Coast - The Woodlands
Florida
- Florida Cancer Specialists - Lake Nona - Orlando
- Florida Cancer Specialists - Sarasota - Sarasota
New York
- NYU Langone Health - New York
- Icahn School of Medicine at Mount Sinai - New York
Pennsylvania
- University of Pennsylvania - Philadelphia
- Sidney Kimmel Cancer Center - Philadelphia
Colorado
- SCRI HealthOne - Denver
Illinois
- University of Chicago - Chicago
Oklahoma
- Oklahoma University - Oklahoma City
Tennessee
- Tennessee Oncology - Nashville - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2022-10-10 |
| Est. Completion | 2028-04-01 |
| Phase | Phase 1 |
What NCT05557045 shows while recruiting
NCT05557045 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (51% higher).
The record links to 3 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which JZP815 is the first listed.
NCT05557045 lists 14 locations in 9 states (Texas, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT05557045 about?
NCT05557045 is a clinical study titled "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815". This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
What is the current status of trial NCT05557045?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 332 participants. The study started on 2022-10-10. Estimated completion is 2028-04-01.
What conditions does trial NCT05557045 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT05557045?
The interventions under investigation include: JZP815 (DRUG).
Who is sponsoring clinical trial NCT05557045?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05557045 being conducted?
This trial has 14 study locations across Colorado, Florida, Illinois, New York, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05557045's enrollment target sits among peer trials
332 17th of 196 higher than 180 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI